DCC5298 |
Uck2-in-135546812 |
Novel non-competitive UCK2 inhibitor, suppressing nucleoside salvage in cells both in the presence and absence of DHODH inhibitors |
|
DCC5299 |
Uck2-in-20874830 |
Novel non-competitive UCK2 inhibitor, suppressing nucleoside salvage in cells both in the presence and absence of DHODH inhibitors |
|
DCC5300 |
ucl-1972 |
Histamine H3 Receptor Antagonist in Treatments of Cognition Disorders |
|
DCC5301 |
Ucl-2190 Hydrogen Maleate |
The first potent nonimidazole H3 receptor antagonist (pKi=8.40) |
|
DCC5302 |
Ucm-05194 |
Novel Agonist of the Type 1 Lysophosphatidic Acid Receptor (LPA1), Showing Efficacy in Neuropathic Pain Amelioration |
|
DCC5303 |
Ucm-1336 |
Novel potent isoprenylcysteine carboxylmethyltransferase (ICMT) inhibitor, improving survival in Ras-driven acute myeloid leukemia |
|
DCC5304 |
Ucm710 |
Dual inhibitor of fatty acid amide hydrolase (FAAH) and α/β hydrolase domain 6 (ABHD6) |
|
DCC5305 |
Ucn-02 |
Stereoisomer of UCN-01, inhibiting protein kinase C with a slightly reduced potency than UCN-01 |
|
DCC5306 |
Ucp1172 |
Novel dual inhibitor of dihydrofolate reductase (DHFR) and its functional analog, Rv2671 |
|
DCC5307 |
Ucph-102f |
Fluorescent excitatory amino acid transporter subtype 1 (EAAT1) selective inhibitor |
|
DCC5308 |
Ue2316 |
Potent and selective 11ß-HSD1 inhibitor, improving memory, including after intracerebroventricular drug administration to the central nervous system alone |
|
DCC5309 |
Ufp512 |
Novel selective delta-opioid receptor agonist |
|
DCC5310 |
Ufr2709 |
Novel Nicotinic Acetylcholine Receptor Antagonist, Inhibiting Nicotine Reward and Decreases Anxiety and Decreasing Ethanol Intake in Alcohol-Preferring Rats |
|
DCC5311 |
Ugm-in-1 |
Novel inhibitor of UGM, impeding C. glutamicum growth |
|
DCC5312 |
Ugm-in-2 |
Novel inhibitor of UGM, impeding C. glutamicum growth |
|
DCC5313 |
Uic-94003 |
Novel potent human immunodeficiency virus type 1 (HIV-1) protease inhibito |
|
DCC5314 |
Uk-447841 |
Selective NEP inhibitor for treatment of the symptoms of Female sexual arousal disorder (FSAD) |
|
DCC5315 |
Uk-505749 |
Selective NEP inhibitor for treatment of the symptoms of Female sexual arousal disorder (FSAD) |
|
DCC5316 |
Ukcp-110 |
Potent VMAT2 inhibitor |
|
DCC5317 |
Ul-766 |
Novel chemically stable fluorescent marker of the ureter |
|
DCC5318 |
Um1024 |
Novel Vaccine Adjuvant for Mycobacterium tuberculosis |
|
DCC5319 |
Umb103 |
Novel potent and selective dual PLK1 and BRD4 inhibitor, inducing apoptosis in pediatric tumor cell lines, leading to significant tumor regression |
|
DCC5320 |
Umb298 |
Novel, Potent, and Selective CBP/P300 Inhibitor |
|
DCC5321 |
Umc160 |
Novel Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitor |
|
DCC5322 |
Um-c162 |
Novel anti-virulence agent, rescuing nematodes from a Staphylococcus aureus infection and preventing the formation of biofilm in a dose-dependent manner without interfering with bacterial viability |
|
DCC5323 |
Unag Ligand |
Novel fluorescent UnaG ligand, binding UnaG with high affinity (Kd = 3 nM) to induce a 2.5-fold fluorescence intensity enhancement and a 10 nm red shift |
|
DCC5324 |
Unbs3157 |
Novel nonhematotoxic DNA intercalating agent with potent antitumor activity, inducing apoptosis via inhibition of key proteins in the PI3K/Akt/mTOR signaling pathway |
|
DCC5325 |
Unc0737
Featured
|
UNC0737 is a negative control of UNC0638 and the N-methyl analog of UNC0638. UNC0737 was designed to eliminate the hydrogen bond interaction seen in the G9a-UNC0224 cocrystal structure between Asp1083 of G9a and the secondary amino group at the 4-position of UNC0224's quinazoline ring3. UNC0737 was >300-fold less potent than UNC0638 in G9a and GLP biochemical assays. As expected, UNC0737 was a poor inhibitor of G9a (IC50 = 5,000 ± 200 nM (n = 2)) and GLP (IC50 > 10,000 nM (n = 2)) in the SAHH-coupled assays. |
|
DCC5326 |
Unc0965 |
Biotinylated UNC0638, enabling chemiprecipitation of G9a from whole cell lysates |
|
DCC5327 |
Unc10112731 |
Novel MYC protein stablizer, increasing the abundance of endogenous MYC proteintargeting the receptor tyrosine kinases KIT and platelet-derived growth factor receptor α (PDGFRα) |
|